Characteristics and clinical applications of Wharton's jelly-derived mesenchymal stromal cells - PubMed

Review

Characteristics and clinical applications of Wharton's jelly-derived mesenchymal stromal cells

L L Liau et al. Curr Res Transl Med. 2020 Jan.

Abstract

Mesenchymal stromal cells (MSCs) are widely used in the clinic because they involve fewer ethical issues and safety concerns compared to other stem cells such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). MSCs derived from umbilical cord Wharton's jelly (WJ-MSCs) have excellent proliferative potential and a faster growth rate and can retain their multipotency for more passages in vitro compared to adult MSCs from bone marrow or adipose tissue. WJ-MSCs are used clinically for repairing tissue injuries of the spinal cord, liver and heart with the aim of regenerating tissue. On the other hand, WJ-MSCs are also used clinically to ameliorate immune-mediated diseases based on their ability to modulate immune responses. In the field of tissue engineering, WJ-MSCs capable of differentiating into multiple cell lineages have been used to produce a variety of engineered tissues in vitro that can then be transplanted in vivo. This review discusses the characteristics of WJ-MSCs, the differences between WJ-MSCs and adult MSCs, clinical studies involving WJ-MSCs and future perspectives of WJ-MSC research and clinical applications. To summarize, WJ-MSCs have shown promise in treating a variety of diseases clinically. However, most clinical trials/studies reported thus far are relatively smaller in scale. The collected evidence is insufficient to support the routine use of WJ-MSC therapy in the clinic. Thus, rigorous clinical trials are needed in the future to obtain more information on WJ-MSC therapy safety and efficacy.

Keywords: Cell therapy; Clinical; Mesenchymal stromal cells; Umbilical cord; Wharton’s jelly.

Similar articles

• Differential expression of cell cycle and WNT pathway-related genes accounts for differences in the growth and differentiation potential of Wharton's jelly and bone marrow-derived mesenchymal stem cells.

  Batsali AK, Pontikoglou C, Koutroulakis D, Pavlaki KI, Damianaki A, Mavroudi I, Alpantaki K, Kouvidi E, Kontakis G, Papadaki HA. Batsali AK, et al. Stem Cell Res Ther. 2017 Apr 26;8(1):102. doi: 10.1186/s13287-017-0555-9. Stem Cell Res Ther. 2017. PMID: 28446235 Free PMC article.

• Isolation and characterization of Wharton's jelly-derived multipotent mesenchymal stromal cells obtained from bovine umbilical cord and maintained in a defined serum-free three-dimensional system.

  Cardoso TC, Ferrari HF, Garcia AF, Novais JB, Silva-Frade C, Ferrarezi MC, Andrade AL, Gameiro R. Cardoso TC, et al. BMC Biotechnol. 2012 May 4;12:18. doi: 10.1186/1472-6750-12-18. BMC Biotechnol. 2012. PMID: 22559872 Free PMC article.

• Wharton's Jelly Mesenchymal Stromal Cells from Human Umbilical Cord: a Close-up on Immunomodulatory Molecules Featured In Situ and In Vitro.

  Corsello T, Amico G, Corrao S, Anzalone R, Timoneri F, Lo Iacono M, Russo E, Spatola GF, Uzzo ML, Giuffrè M, Caprnda M, Kubatka P, Kruzliak P, Conaldi PG, La Rocca G. Corsello T, et al. Stem Cell Rev Rep. 2019 Dec;15(6):900-918. doi: 10.1007/s12015-019-09907-1. Stem Cell Rev Rep. 2019. PMID: 31741193

• Wharton's jelly-derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications.

  Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan CV. Kim DW, et al. Int J Mol Sci. 2013 May 31;14(6):11692-712. doi: 10.3390/ijms140611692. Int J Mol Sci. 2013. PMID: 23727936 Free PMC article. Review.

• Mesenchymal stem cells derived from Wharton's Jelly of the umbilical cord: biological properties and emerging clinical applications.

  Batsali AK, Kastrinaki MC, Papadaki HA, Pontikoglou C. Batsali AK, et al. Curr Stem Cell Res Ther. 2013 Mar;8(2):144-55. doi: 10.2174/1574888x11308020005. Curr Stem Cell Res Ther. 2013. PMID: 23279098 Review.

Cited by

• Treatment of spinal cord injury with mesenchymal stem cells.

  Liau LL, Looi QH, Chia WC, Subramaniam T, Ng MH, Law JX. Liau LL, et al. Cell Biosci. 2020 Sep 22;10:112. doi: 10.1186/s13578-020-00475-3. eCollection 2020. Cell Biosci. 2020. PMID: 32983406 Free PMC article. Review.

• Stem Cell-Based Therapy for Asherman Syndrome: Promises and Challenges.

  Gao Y, Wu G, Xu Y, Zhao D, Zheng L. Gao Y, et al. Cell Transplant. 2021 Jan-Dec;30:9636897211020734. doi: 10.1177/09636897211020734. Cell Transplant. 2021. PMID: 34105392 Free PMC article. Review.

• A Three-Dimensional Xeno-Free Culture Condition for Wharton's Jelly-Mesenchymal Stem Cells: The Pros and Cons.

  Koh B, Sulaiman N, Fauzi MB, Law JX, Ng MH, Yuan TL, Azurah AGN, Mohd Yunus MH, Idrus RBH, Yazid MD. Koh B, et al. Int J Mol Sci. 2023 Feb 13;24(4):3745. doi: 10.3390/ijms24043745. Int J Mol Sci. 2023. PMID: 36835154 Free PMC article.

• Management of Retinitis Pigmentosa Via Wharton's Jelly-Derived Mesenchymal Stem Cells or Combination With Magnovision: 3-Year Prospective Results.

  Ozmert E, Arslan U. Ozmert E, et al. Stem Cells Transl Med. 2023 Oct 5;12(10):631-650. doi: 10.1093/stcltm/szad051. Stem Cells Transl Med. 2023. PMID: 37713598 Free PMC article.

• Mesenchymal Stem Cells and Tissue Bioengineering Applications in Sheep as Ideal Model.

  Muniz TDTP, Rossi MC, de Vasconcelos Machado VM, Alves ALG. Muniz TDTP, et al. Stem Cells Int. 2024 Oct 18;2024:5176251. doi: 10.1155/2024/5176251. eCollection 2024. Stem Cells Int. 2024. PMID: 39465229 Free PMC article. Review.

Publication types

MeSH terms